Table 1. Baseline Patient Characteristics.
| Characteristic | n | % |
|---|---|---|
| Gender | ||
| Men | 31 | 22.6 |
| Women | 106 | 77.4 |
| Race | ||
| White | 118 | 86.1 |
| Asian | 13 | 9.5 |
| Black | 4 | 2.9 |
| Hispanic | 0 | 0.0 |
| Other/Unknown | 2 | 1.5 |
| Smoking status | ||
| Never | 77 | 56.2 |
| Former | 55 | 40.1 |
| Current | 5 | 3.6 |
| Median agea (range), years | 60 (35-84) | |
| Stageb | ||
| Relapsedc | 31 | 22.6 |
| IVAb | 42 | 30.7 |
| IVBb | 64 | 46.7 |
| Presence of Extrathoracic Metastasis | ||
| Yes | 79 | 57.7 |
| No (without/with pleural effusion) | 58 (29/29) | 42.3 |
| Involved Metastatic Sites | ||
| Liver | 21 | 15.3 |
| Adrenal | 4 | 2.9 |
| Bone | 59 | 43.1 |
| Brain | 30 | 21.9 |
| EGFR Mutation | ||
| Exon 19 Deletion | 76 | 55.5 |
| L858R | 47 | 34.3 |
| L861 | 7 | 5.1 |
| G719 | 4 | 2.9 |
| L861+G719 | 2 | 1.5 |
| L858R+T790M | 1 | 0.7 |
| EGFR-TKI | ||
| Erlotinib | 121 | 88.3 |
| Gefitinib | 16 | 11.7 |
| Line of EGFR TKI | ||
| First-Line | 93 | 67.9 |
| Second-Line | 38 | 27.7 |
| Third- or Greater-Line | 6 | 4.4 |
a
Age at diagnosis of metastatic disease.
b
American Joint Committee on Cancer (AJCC) Staging System, 7th edition.
c
Patients with stages I-III with systemic relapse following definitive therapy.